Making a case for the combined use of SGLT2 inhibitors and GLP1 receptor agonists for cardiorenal protection
Vikas S. Sridhar(University Health Network), David Z.I. Cherney(University Health Network), Lisa Dubrofsky(University of Toronto), Jacinthe Boulet(Montreal Heart Institute)
Cited by 15
Related Papers
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
|The Lancet|2022|969
Sodium Glucose Cotransporter-2 Inhibition in Heart Failure
|Circulation|2017|459
Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial
|Nephrology Dialysis Transplantation|2019|216
The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics
|Nephrology Dialysis Transplantation|2020|189
Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials
|The Lancet Diabetes & Endocrinology|2024|135